A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia
| Autor: | Xijing Lu, Yan Li, Hui Sun, Ting Niu, Yongqiang Zhao, Zhao Wang, Renchi Yang, Ming Hou, Depei Wu, Xiequn Chen, Zhi-Xiang Shen, Ping Zou, Shujie Wang, Naibai Chang, Yin Zhang, Gaokui Zhang, Li Yu |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Splenectomy Gastroenterology law.invention Young Adult Randomized controlled trial law Internal medicine medicine Humans Platelet Adverse effect Aged Danazol Hematology Platelet Count business.industry Recombinant Human Thrombopoietin Middle Aged Thrombocytopenia Recombinant Proteins Surgery Clinical trial Treatment Outcome Thrombopoietin Female business medicine.drug |
| Zdroj: | International Journal of Hematology. 96:222-228 |
| ISSN: | 1865-3774 0925-5710 |
| Popis: | This multicenter, randomized trial assessed the efficacy and safety of a recombinant human thrombopoietin (rhTPO) in patients with persistent primary immune thrombocytopenia (ITP) who had failed glucocorticosteroid treatment. A total of 140 eligible patients were randomized to receive rhTPO + danazol (rhTPO group, 73 patients) or danazol (control group, 67 patients) alone. During the first phase, the increase in the mean maximal platelet counts (101.2 × 10(9)/L) and the area under curve (749.6) in the rhTPO group were significantly higher compared to control (33.3 × 10(9)/L and 316.2; P = 0.0060 and 0.0000, respectively). The major response rate (MRR) and total response rate (TRR) in the rhTPO group were 38.4 and 60.3 %, respectively, significantly higher than in control (MRR 7.9 %, P = 0.0003; TRR 36.5 %, P = 0.0104). In the control group, 45 patients with platelet counts |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink